FARMINGDALE, N.Y., Jan. 31, 2013 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, cranial maxillo – facial surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, has been selected to present at the first ever MicroCapClub Invitational, an online forum featuring unique microcap companies.
The Misonix presentation can be accessed at the following link: http://microcapclub.com/2013/01/microcapclub-invitational-misonix-mson/
"At MicroCapClub we have more than 160 experienced microcap investors highlighting over 90 microcap companies in our members forum. As a group, we thought it would be instructive to showcase a number companies we believe are highly unique," said Ian Cassel , founder of MicroCapClub. "We have been following Misonix since last November, and we believe the company's ultrasonic surgical devices will continue to gain market share in 2013 and beyond."
"We are pleased to participate in this first ever event," said Michael A. McManus, Jr. , president and chief executive officer of Misonix. "We welcome the opportunity to introduce Misonix to a universe of potential new investors."
About MicroCapClub:The MicrocapClub (mc2) is an exclusive microcap forum focused on microcap companies (sub $300m market cap). The MicroCapClub was created and founded by Ian Cassel as a way to share ideas and to learn from other seasoned like-minded microcap investors. Our goal at MicroCapClub is quality membership and quality stock ideas. If you are an experienced microcap investor, feel free to Apply Today. Go to www.microcapclub.com for additional information.
About MisonixMisonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor StatementWith the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.Investor Relations Contacts Misonix Contact:Lytham Partners, LLCRichard ZarembaRobert Blum, Joe Dorame, Joe Diaz631-694-9555
|SOURCE Misonix, Inc.|
Copyright©2012 PR Newswire.
All rights reserved